Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stem Holdings's revenue per share for the
three
months ended in Sep. 2023 was $-4.21.
Stem Holdings's revenue per share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.63.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Stem Holdings's Revenue per Share or its related term are showing as below:
STMH's 3-Year Revenue Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.8 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Stem Holdings Revenue per Share Related Terms
Stem Holdings Revenue per Share Historical Data
* Premium members only.
The historical data trend for Stem Holdings's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STMH vs NXEN, VFRM, ENDPQ: Revenue per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stem Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Holdings PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stem Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Stem Holdings's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Stem Holdings's Revenue Per Share for the fiscal year that ended in Sep. 2023 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stem Holdings (STMH) has a Revenue per Share of $0.63 as of Sep. 2023. Revenue per share equals the per-share value of a company's sales. View historical data on Stem Holdings and its competitors.
Is Stem Holdings' Revenue per Share too high?
Stem Holdings' current Revenue per Share is $0.63. The Drug Manufacturers industry median Revenue per Share is 3.80. Stem Holdings' value of $0.63 is 83.4% below this industry median. Overall, Stem Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Stem Holdings' Revenue per Share compare to NXEN and VFRM?
Stem Holdings' Revenue per Share of $0.63 can be compared against companies in the Drug Manufacturers industry. The industry median Revenue per Share is 3.80. Stem Holdings' value of $0.63 is 83.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.80, based on 903 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stem Holdings's current Revenue per Share of $0.63 is 83.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Stem Holdings and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Holdings's current Revenue per Share is $0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Holdings stock overvalued right now?
Stem Holdings (STMH) has a current Revenue per Share of $0.63. The current Revenue per Share is $0.63 and 83.4% below the Drug Manufacturers industry median of 3.80. Stem Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Stem Holdings (STMH), the current Revenue per Share is $0.63 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stem Holdings Inc is involved in a cannabis business. The company is engaged in the manufacture, possession, sale, distribution, and branding of cannabis and its related products. Its brand includes TJ's Gardens; Yerba Buena; Cannavore; Dose-ology and Travis X James.
12GF Score
Get the complete analysis for STMH
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STMH has been successfully added to your 
